• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Genos Unveils Crowdsourcing Platform for Genomics R&D

by Jasmine Pennic 12/15/2016 Leave a Comment

Genos Unveils Crowdsourcing Platform for Genomics R&D

Genos, a community for personal genetic discovery and research has announced the public launch of its crowdsourcing platform for genomics research and development. The Genos platform will enable individuals to sequence their genetic profiles with 50 times more data than current popular sequencing options, while empowering individuals to participate in groundbreaking research projects on their own terms. 

As part of the platform launch, Genos revealed several initial research partners and projects, including: 

·  NantBioScience: a Phase I clinical trial for lymphoma, and a Phase I study of a vaccine for HER-2 expressing breast cancer

·  NantKwest: a Phase II study of a therapy for stage IIIB or IV Merkel Cell Carcinoma

·  Broad Institute: working to understand genetic variants of the prion protein in order to protect against prion disease

·   The Utah Foundation for Biomedical Research: studying genetic variances of common neurological and psychiatric disorders to guide treatment, including Tourette syndrome, autism, ADHD and others

Genos will enable individuals in all studies to retain control over whether and how their genomic data is used in academic and commercial research, and to receive compensation for voluntary participation in research projects. 

“Cultivating a community around genomics research promises to illuminate the genetic underpinnings of the human condition, including finding cures to our most elusive diseases,” said Mark Blumling, co-founder and CEO of Genos. “It also engages people in their own healthcare like never before. To realize this great potential, we must remove the barriers to accelerating research, and the only way to do that is by putting consent and control over personal genomics data where it belongs—in the hands of individuals.” 

The newly launched Genos platform will enable anyone to sequence their exome ($499), the part of the genome containing about 80 percent of all known genetic variants associated with disease via a simple saliva sample, and then explore their specific genetic profiles through web-based visualization.

By sequencing the exome rather than a small snippet of the genome, individuals get a more comprehensive picture of their genetic blueprints and are able to use that same data for a lifetime of discovery without re-sequencing. Genos will also make available access to genetic counselors for consultations about individuals’ personal genetics.

Genos participants can browse studies from academic and commercial researchers to determine which efforts, if any, will receive access to their personal genomic information. Consenting individuals receive transparent compensation for research studies in which they participate. This model also includes a pay-it-forward option that helps friends and family or disease-specific patients also get sequenced. This is a significant departure from current models, which use broad consent requirements to resell genomic data without input from, or compensation for, individuals. 

“Genos’ goal is to build the world’s largest community of empowered, consenting, sequenced individuals, which will have a significant impact on the industry,” said George Church, PhD, Professor of Genetics at Harvard Medical School and MIT. “If we want to shorten the time to medical cures, we need to break down the silos between genomic data and research and move ownership to the individual. The best way to do that is to foster the relationship between individuals and the research community, which is precisely what Genos is doing.” 

Prior to the launch, Genos announced a $6 million strategic investment from NantOmics, a wholly owned subsidiary of healthcare and technology company NantWorks.

Tagged With: Cancer Genomics, crowdfunding in healthcare, genomics data, Genos, Healthcare Crowdfunding, Medical crowdsourcing

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |